Its biggest would-be competitor is ivonescimab, a medicine being developed in the U.S. by Summit Therapeutics. It delivered positive clinical trial results in China in a phase 3 study in which it went ...

Super Micro Computer's valuation and growth prospects signal recovery despite challenges. Read for my SMCI stock's earnings ...